In AD, JAK inhibitors are therapeutic agents and interfere with, for example, IL‐4/IL‐13 signaling, TSLP, IL‐5, and IL‐31 signaling, the generation of inflammatory dendritic epidermal cells (IDEC) and have multiple inflammatory modes of action [28, 29, 30, 31]. This evidence concerns the gene IL13 and Alzheimer disease.